Drug Profile
Research programme: fibroblast activation protein antagonists - Vantia Therapeutics
Alternative Names: FE 999040; VA-FAPiLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Vantia Therapeutics
- Class
- Mechanism of Action Fibroblast activation protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Europe (PO)